Long-term safety assessment of live attenuated tetravalent dengue vaccines: Deliberations from a WHO technical consultation

Vaccine

Volumn 31, Issue 23, 2013, Pages 2603-2609

  Bentsi Enchill, Adwoa D ^a   Schmitz, Julia ^a   Edelman, Robert ^b   Durbin, Anna ^c   Roehrig, John T ^d   Smith, Peter G ^e   Hombach, Joachim ^a   Farrar, Jeremy ^f  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b University of Maryland School of Medicine Center for Vaccine Development   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

Author keywords

Dengue vaccine; Post licensure monitoring; Vaccine safety

Indexed keywords

DENGUE VACCINE; LIVE VACCINE;

ANTIBODY TITER; ARTICLE; CLINICAL TRIAL (TOPIC); DENGUE; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOLLOW UP; HERD IMMUNITY; HUMAN; MEDICAL DOCUMENTATION; MEDICAL ETHICS; MEDICAL EXPERT; PATIENT MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; RISK ASSESSMENT; STUDY DESIGN; VACCINATION; VIRUS TRANSMISSION;

EID: 84878362029     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.03.038     Document Type: Article

References (49)

1. WHO Dengue: guidelines for diagnosis, treatment, prevention and control 2009, World Health Organization, Geneva, WHO/HTM/NTD/DEN/2009.1.
2. Whitehorn J., Farrar J. Dengue. Br Med Bull 2010, 95:161-173.
3. WHO. Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated). Geneva: World Health Organization; 2011. WHO/BS/11.2159.
4. WHO. Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated). Geneva, World Health Organization. WHO/BS/11.2159, in press.
5. Coller B.-A.G., Clements D.E. Dengue vaccines: progress and challenges. Curr Opin Immunol 2011, 23:391-398.
6. Schmitz J., Roehrig J., Barrett A., Hombach J. Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine 2011, 29:7276-7284.
7. Guy B., Barrere B., Malinowski C., Saville M., Teyssou R., Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29:7229-7241.
8. Pierson T.C., Fremont D.H., Kuhn R.J., Diamond M.S. Structural Insights into the mechanisms of antibody-mediated neutralization of flavivirus Infection: implications for vaccine development. Cell Host Microbe 2008, 4:229-238.
9. Whitehorn J., Simmons C.P. The pathogenesis of dengue. Vaccine 2011, 29:7221-7228.
10. Murphy B.R., Whitehead S.S. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 2011, 29:587-619.
11. Thomas S.J., Endy T.P. Critical issues in dengue vaccine development. Curr Opin Infect Dis 2011, 24:442-450.
12. Gibbons R.V., Kalanarooj S., Jarman R.G., Nisalak A., Vaughn D.W., Endy T.P., et al. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg 2007, 77:910-913.
13. Guzmán M.G., Kouri G., Valdés L., Bravo J., Vásquez S., Halstead S.B. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica 2002, 11:223-227.
14. Halstead S.B. Immune enhancement of viral infection. Prog Allergy 1982, 31:301-364.
15. Halstead S.B., Mahalingam S., Marovich M.A., Ubol S., Mosser D.M. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis 2010, 10:712-722.
16. Halstead S.B., O'Rourke D.E.J. Dengue viruses and mononuclear phagocytes: infection enhancement by non-neutralizing antibody. J Exp Med 1977, 146:201-217.
17. Thomas S.J., Hombach J., Barrett A. Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development. Vaccine 2009, 27:355-368.
18. Rothman A.L. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 2011, 11:532-543.
19. Avirutnan P., Punyadee N., Noisakran S., Komoltri C., Thiemmeca S., Auethavornanan K., et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 2006, 193:1078-1088.
20. WHO Guidelines for the clinical evaluation of dengue vaccines in endemic areas 2008, World Health Organization, Geneva, WHO/IVB/08.12.
21. Sun W., Cunningham D., Wasserman S.S., Perry J., Putnak J.R., Eckels K.H., et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccin 2009, 5:33-40.
22. Durbin A.P., Kirkpatrick B.D., Pierce K.K., Schmidt A.C., Whitehead S.S. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 2011, 29:7242-7250.
23. Morrison D., Legg T.J., Billings C.W., Forrat R., Yoksan S., Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010, 201:370-377.
24. Capeding R.Z., Luna I.A., Bomasang E., Lupisan S., Lang J., Forrat R., et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 2011, 29:3863-3872.
25. Watanaveeradej V., Simasathien S., Nisalak A., Endy T.P., Jarman R.G., Innis B.L., et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants. Am J Trop Med Hyg 2011, 85:341-351.
26. Poo J., Galan F., Forrat R., Zambrano B., Lang J., Dayan G. Live-attenuated tetravalent dengue vaccine in dengue-naïve children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J 2011, 30:e9-e17.
27. Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380:1559-1567.
28. Monath T.P., Cetron M.S., Teuwen D.E. Yellow fever vaccine. Vaccines 2008, 959-1055. Saunders Elsevier, Philadelphia, PA. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
29. Guzmán M.G., Kouri G. Dengue: an update. Lancet Infect Dis 2001, 2:33-42.
30. Meltzer E., Heyman Z., Bin H., Schwartz E. Capillary leakage in travelers with dengue infection: implications for pathogenesis. Am J Trop Med Hyg 2012, 86:536-539.
31. Guzmán M.G., Kouri G., Bravo J., Valdes L., Vasquez S., Halstead S.B. Effect of age on outcome of secondary dengue 2 infections. Int J Infect Dis 2002, 6:118-124.
32. Hammond S.N., Balmaseda A., Pérez L., Tellez Y., Saborío S.I., Mercado J.C., et al. Differences in dengue severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua. Am J Trop Med Hyg 2005, 73:1063-1070.
33. Anders K.L., Nguyet N.M., Chau N.V.V., Hung N.T., Thuy T.T., Lien L.B., et al. Epidemiological factors associated with dengue shock syndrome and mortality in hospitalized dengue patients in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg 2011, 84:127-134.
34. Khor C.C., Chau T.N.B., Pang J., Davila S., Long H.T., Ong R.T.H., et al. Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1. Nat Genet 2011, 43:1139-1141.
35. Fried J.R., Gibbons R.V., Kalayanarooj S., Thomas S.J., Srikiatkhachorn A., Yoon I.-K. Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006. PLoS Negl Trop Dis 2010, 4:e617.
36. Duyen H.T.L., Ngoc T.V., Ha D.T., Hang V.T.T., Kieu N.T.T., Young P.R., et al. Kinetics of plasma viremia and soluble nonstructural protein 1 concentrations in dengue: differential effects according to serotype and immune status. J Infect Dis 2011, 203:1292-1300.
37. Anderson K., Gibbons R.V., Rothman A.L., Berkelman R., Endy T.P. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a prospective school-based cohort in Thailand. Int J Infect Dis 2012, 16S1:40.035. [abstract].
38. Blaney J.E., Matro J.M., Murphy B.R., Whitehead S.S. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 2005, 79:5516-5528.
39. Wahala W.M.P.B., Kraus A.A., Haymore L.B., Accavitti-Loper M.A., de Silva A.M. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 2009, 392:103-113.
40. Simmons C.P., Farrar J.J., Chau NvV, Wills B. Dengue. N Engl J Med 2012, 366:1423-1432.
41. The Gambia Hepatitis Study Group The Gambia hepatitis intervention study. Cancer Res 1987, 47:5782-5787.
42. Extended follow-up of young women in Costa Rica who received vaccination against human papillomavirus types 16 and 18 and unvaccinated controls. (NCT ID:) [accessed 28.05.12]. ctgov:NCT00867464.
43. Madhi S.A., Adrian P., Kuwanda L., Jassat W., Jones S., Little T., et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2007, 25:2451-2457.
44. Cunliffe N.A., Witte D., Ngwira B.M., Todd S., Bostock N.J., Turner A.M., et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine 2012, 30S:A36-A43.
45. Brown C.A., Lilford R.J. The stepped wedge trial design: a systematic review. BMC Med Res Methodol 2006, 6:54.
46. Farrington C.P. Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine 2004, 22:2064-2070.
47. WHO Global vaccine safety blueprint 2012, World Health Organization, Geneva, WHO/IVB/12.07.
48. Peeling R.W., Artsob H., Pelegrino J.L., Buchy P., Cardosa M.J., Devi S., et al. Evaluation of diagnostic tests: Dengue. Nat Rev Microbiol 2010, 8(Suppl):S30-S38.
49. WHO-VMI Dengue Vaccine Modeling Group Assessing the potential of a candidate dengue vaccine with mathematical modeling. PLoS Negl Trop Dis 2012, 6:e1450.